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Abstract
Chloro-4-phenyl thiomethylene bisphos-
phonate (tiludronate) is a new drug which can
be used as an inhibitor of bone resorption. As
it remains in bone for a long time, and as
mineralisation defects have only been seen at
doses much higher than those required to
decrease osteoclastic activity, it could be
given at high doses over a short period of
time.
Eighteen patients with Paget's disease of
bone were randomly allocated to three thera-
peutic groups receiving respectively 600, 800,
and 1200 mg/day tiludronate for five days.
Serum alkaline phosphatase activity and the
urinary hydroxyproline/creatinine ratio were
quickly and drastically reduced in all three
groups. A significant reduction of serum
alkaline phosphatases and the hydroxyproline/
creatinine ratio was still present six months
after the five day therapeutic course, reflecting
a sustained activity of tiludronate even after
stopping treatment. Dose dependent short
and long term reductions of bone turnover
rate were observed.
Biochemical assessment of haematological,
renal, or hepatic tolerance did not show any
toxicity of tiludronate. Fifty per cent of
patients treated by a dose of 1200 mg/day
reported gastrointestinal disturbances, how-
ever, making this dosage unsuitable for clinical
practice.

























Bisphosphonates inhibit bone resorption and
have been reported to be effective in the
treatment of Paget's disease of bone with a dose
dependent response. '` Hydroxyethylidene
bisphosphonate is the most widely available
bisphosphonate and is extensively used in the
treatment of Paget's disease of bone.' Its use
may lead, however, in particular with higher
doses, to the inhibition ofbone mineralisation.8 9
This has led to the development of other
bisphosphonates that may inhibit bone resorp-
tion without interference with the mineralisation
of bone. Tiludronate (chloro-4-phenyl thio-
methylene bisphosphonate) is a bisphosphonate
now available for clinical testing. This bis-
phosphonate has been assayed in different
models of bone resorption in animals'0 and
mineralisation defects were only seen at much
higher doses than those required to decrease
bone resorption. " In Paget's disease of bone a
six month course of tiludronate by mouth is able
to reduce bone turnover without important side
effects.'2"3 Furthermore, several studies have
shown that treatment of Paget's disease of bone
with short term courses of bisphosphonate may
induce a sustained therapeutic effect.7 We
therefore, investigated the effect of three doses
of tiludronate given by mouth for five days to
patients with Paget's disease of bone.
Patients and methods
Eighteen patients presenting radiological and
scintigraphic evidence of Paget's disease of bone
in one (three patients) or more (15 patients)
bones were included in this study after in-
formed consent (table). All patients had active
Paget's disease as judged by increased serum
activity of alkaline phosphatases and urinary
excretion of hydroxyproline. Before this study,
10 patients had never been treated for Paget's
disease of bone, salmon calcitonin had been
used to treat five patients (dose ranging from 50
IU intramuscularly three times a week to 200
IU/day nasally for three to six months), hydroxy-
ethylidene bisphosphonate had been used for
four patients (5 mg/kg/day for six months),
and one patient had received aminohydroxy-
propylidene bisphosphonate (250 mg/kg/day for
six weeks). None of the patients had shown a
normal value of serum alkaline phosphatases
during previous treatments. A washout period
of six months for calcitonin, three years for
hydroxyethylidene bisphosphonate, and five
years for aminohydroxypropylidene was res-
pected before inclusion in the present study. All
patients had relapsed as judged by a progressive
increase in serum alkaline phosphatases of at
least 20% from the lowest values reached with
previous treatment.
Serum alkaline phosphatases were assessed
by the method of Trayser and Seligson"4
(normal range 40-135 IU/1). After an overnight
fast and voiding the bladder, the urine produced
over a two hour period was collected for
measurement of hydroxyproline (Kit Hypro-
nostikon Teknika, Organon, Oss-Boxtel, The
Netherlands). The hydroxyproline concen-
tration was expressed as a ratio to creatinine
excretion'5 (normal range 0-24 mg/g).
Patients were randomly assigned to three
therapeutic groups, each containing six patients
They were treated for five consecutive days
receiving respectively 600 mg/day (Gr600),
800 mg/day (Gr800), and 1200 mg/day (Grl200)
tiludronate by mouth. In the present study, we
used a new formulation of tiludronate with a
bioavailability twice as high (4-8% of the
ingested dose) than that used in our previous
studies,'3 16 for which the estimated bio-
availability of tiludronate was between 2 and 4%
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of the ingested dose. Tiludronate was taken two
hours before and after any food ingestion and
only with 200 ml of deionised water (Spa
Reine). Serum alkaline phosphatases and the
hydroxyproline/creatinine ratio were assessed
before the first intake of tiludronate (day 1) and
on each subsequent day of treatment (days 2,
3, 4, and 5). These parameters were also
measured after the discontinuation oftiludronate
at two (day 14), three (day 21), four (day 28),
eight (day 56), 13 (day 90), 17 (day 120), 21 (day
150), and 25 (day 180) weeks after the beginning
of the experimental procedure. Simultaneously,
an analysis of biochemical parameters reflecting
the haematological, renal, and hepatic functions
and an exhaustive clinical evaluation were
performed at each visit. All values of the
hydroxyproline/creatinine ratio and serum
alkaline phosphatases are expressed as mean
(SEM) values and as a percentage of the values
of serum alkaline phosphatases and the
hydroxyproline/creatinine ratio measured at day
1, considered as baseline (100%). In each group
the statistical significance of the variations of
serum alkaline phosphatases and the hydroxy-
proline/creatinine ratio at the different times of
the study were appreciated by the mean of a two
tailed Student's t test whereas the variations of
these parameters in the three groups were
compared by a Zerbe curve-response analysis. 17
Results
Three patients (two in Gr600 and one in Gr800)
refused to come back for the biochemical
investigations and were withdrawn from the
statistical analysis. These three patients were
personally contacted, however, and none had
any side effects during or after tiludronate
treatment. These three patients who dropped
out left 15 patients: four in Gr600, five in
Gr800, and six in Grl200 (table).
At the beginning of the study there was no
statistically significant difference between levels
of serum alkaline phosphatases in the three
groups. This allows us to compare changes in
serum alkaline phosphatases in the three thera-
peutic groups during the study. This was not so
for the hydroxyproline/creatinine ratio, which
was significantly higher in Grl200 patients
compared with the Gr600 group. Levels of
serum alkaline phosphatases were significantly
reduced (p<0 01) after two days of treatment in
Gr600 (mean (SEM) -7-8(2-3)%), after four
days in Gr800 (-29-3(13-8)%), and after one
day in Grl200 (-13-1(4-4)%). The maximum
decrease in serum alkaline phosphatases was
obtained at day 90 in Gr600 (-30-6(8-2)%), at
day 90 in Gr800 (-45-8(9-3)%), and at day 120
in Grl200 (-57-8(3-3%)). At the end of the
follow up (day 180), levels of serum alkaline
phosphatases were still reduced in the three
groups: -25-3(8-7)% in Gr600 (p<005),
-3510(17-5)% in Gr800 (NS), and -57-6(4-1)%
in Grl200 (p<0-02) (fig 1). The analysis of
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Figure I Mean decrease ofserum alkaline phosphatases in
the three groups during thefive day course oftreatment with
tiludronate and six months offollow up. Dose group
coverages are shown.
Baseline datafor all patients in the study. Serum alkaline phosphatases and the hydroxyprolinelcreatinine ratio after three
and six months are given.
Patient Age Sex Previous Bones Serum alkaline phosphatase Urinary hydroxyprolinel
No (years) treatment* affectedt (40-135 IUll) creatinine ratio
(0-24 mg/g)
Day 0 Day 5 Day 180 Day 0 Day S Day 180
Gr 600
1 81 F A 1 182 180 167 27-1 16-1 26-3
2 57 M C+B 1,2,4,7 564 516 489 48-4 39-1 40 7
3 72 M A 1,6,7,8 275 258 179 38-4 24-5 25-1
4 69 F A+B 1,7 785 666 435 28 24-7 22-9
Mean
(SEM) 69-7 (4-9) 451 (137) 412 (115) 317 (84) 35 (5) 26 (4) 28 (4)
Gr 800
1 80 M - 4,5,8 316 291 172 26-2 43-4 17-4
2 60 M A 7 236 208 204 27-4 18-6 19-1
3 53 F - 10 519 422 115 86-3 30-0 30-7
4 50 F B 2,8,12 502 441 206 46-4 41-4 16-1
Mean 66 M - 1,2,4,6 847 760 1026 111-1 124-5 81-7(SEM) 61-8 (5-3) 7,9,10 484 (106) 424 (94) 344 (171) 59 (17) 52 (19) 33 (12)
Gr 1200
1 72 M - 7,9 492 430 260 70-9 35-4 71-2
2 87 F - 1,7,9,10 675 611 386 66-2 51-0 71-1
3 67 M - 2,3,7,9 294 311 114 25-3 16-7 9-3
4 68 F - 1,2,4,7,9 381 404 134 75-8 34-4 40 4
5 63 M - 2,7,8,11 794 679 254 69-3 30-3 33-0
6 57 F - 1,2,7,9 905 805 349 138-9 87-5 73-2
Mean
(SEM) 69 (4-1) 590 (98) 540 (77) 249 (45) 74-4 (15) 43 (10) 50 (11)
*Previous treatment: A=hydroxyethylidene bisphosphonate; B=calcitonin; C=aminohydroxypropylidene.
tBones affected: skull=1; spine=2; sacrum=3; humerus=4; clavicle=5; ulna=6; pelvis=7; scapula=8; femur=9; tibia=10;
sternum= 11; and ribs= 12.
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was shown to induce a decrease in serum
alkaline phosphatases varying from 30% (600
mg/day) to 60% (1200 mg/day). Furthermore,
six months after stopping this short term
treatment the accumulation of tiludronate in
bone and its subsequent release from the matrix
a 600 mg/day gave a sustained therapeutic effect. In the
0 800 mg/day groups receiving 800 or 1200 mg/day, the mean1200 mg/day decrease in serum alkaline phosphatases at that
time (respectively 35 and 57%) was almost
1 5 14 2 28 56 90 180 identical to that described when low doses oftiludronate were given continuously for six
Days months. This confirms the antiosteoclastic
Mean decrease in the hydroxyprolinelcreatinine activity of tiludronate and its linkage to the
the three groups during thefive day course of bone matrix. These findings are in agreement
at with tiludronate and six months offollow up. Dose with a previous report showing that, in healthy
verages are showvn. postmenopausal women, a six month course of
tiludronate by mouth may counteract post-
menopausal bone loss for at least one year by
nce (p=00027) between the decrease of decreasing bone resorption.'6
alkaline phosphatases in Gr600 and Short and long term inhibition of bone
[ with the fluctuations of serum alkaline turnover rates by tiludronate follow a dose
hatases in Gr800 following an intermediate dependent pattern. Indeed, the maximum
n. The hydroxyproline/creatinine ratio decrease in serum alkaline phosphatases and the
so quickly and drastically reduced in the reduction of this parameter reported at the end
therapeutic groups: Gr600 -7 7(2 3)% of the six month follow up are almost twice
two days (p<0 02) with a maximum as high in patients treated with 1200 mg/day
se of
-35-4(6-2)% at day 90 (p<0 01); tiludronate (-57-8(3-3)%; -57-6(4-1)%) than
-29-3(13-8)% (p<005) after four days in subjects who received 600 mg/day (-30-6
a maximum decrease of -40-2(11-4)% (8 2)%; -25-3(8-7)%), whereas patients with
01) at day 90; and Grl200 - 13-1(4-5)% Paget's disease treated by a daily dose of 800 mg
02) after one day with a maximum follow an intermediate pattern (-45-8(9 3)%;
Lse of -40-2(12-0)% (p<0O01) at day 150 -35-0(175)%).
At the end of the study, the decrease in Even with the higher dose of tiludronate,
ydroxyproline/creatinine ratio was still however, the percentage of patients with
significant in Gr600 (-17-9(6-5)%) complete and sustained biochemical remission
D2) and in Grl200 (-33-6(12-2)%) remains low compared with those treated with
)2) whereas in Gr800 the decrease in the other bisphosphonates such as aminohydroxy-
,yproline/creatinine ratio did not reach propylidene, dichloromethylene bisphospho-
ical significance (-29-9 (19-9)%) (NS). nate, and aminohexane bisphosphonateS 18 19
he six month follow up period, only one by mouth for either a short or long period of
t (7%) presented a complete biochemical time. The mean decrease of serum alkaline
ion, assessed by a normalisation of serum phosphatases and the hydroxyproline/creatinine
te phosphatases and the hydroxyproline/ ratio reported with tiludronate is relatively close
line ratio, whereas five (33%) other to that obtained during treatment with calcitonin
ts showed levels of serum alkaline or hydroxyethylidene bisphosphonate.' The
iatases or a hydroxyproline/creatinine absence of fractures in lytic areas of weight-
within the normal range at that time bearing bones and the absence of an increase in
bone pain in the same areas, as described for
significant alteration of biochemical hydroxyethylidene bisphosphonate during treat-
eters reflecting haematological, renal, or ment, might be considered as a relative indication
c metabolism were recorded. Clinically, of the absence of impairment of mineralisation
onate was perfectly tolerated in Gr800 when using these doses of tiludronate.'
Ls, whereas one of six patients (16%) in No limiting side effects occurred in patients
and three of six patients (50%) in Grl200 in Gr600 and Gr800. In Grl200, however, the
ted mild gastrointestinal disturbances high rate (50%) of gastrointestinal disturbances,
uted by mild diarrhoea. Thisphenomenon even if they spontaneously resolved after the
t lead to interruption of the treatment and end of the treatment, is likely to make this dose
neously resolved after the end of the five unsuitable for daily practice. Gastrointestinal
erapeutic course. side effects are also a common feature of
treatment with other bisphosphonates. Nausea
ssion and irritation ofthe gastric mucosa are important
Iuous administration of tiludronate for six side effects of treatment with aminohydroxy-
s has previously been shown to reduce propylidene by mouth which, at a dose of 600
ne turnover rate in Paget's disease of bone mg/day, induces gastritis and oesophagitis in
proximately 40-50%.12 13 In this work a up to 30% of patients.20 With hydroxyethyli-
to six times higher dose (considering a dene bisphosphonate and dichloromethylene
increase in bioavailability for the new bisphosphonate, slight gastric discomfort
nate formulation compared with that and diarrhoea are reported as possible side
n previous work) given for only five days effects.' 21
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In conclusion, treatment with tiludronate by
mouth at high doses for only five days is
followed by a clinical and biochemical response
which is sustained for several months. There is
a dose dependent reduction of bone turnover
rate. Gastrointestinal disturbances, however,
make 1200 mg/day an unsuitable dose for
clinical daily practice. The biochemical reduction
of disease activity, persisting for months after
the end of treatment, confirms the potential
usefulness of tiludronate by mouth as an inter-
mittent treatment for metabolic bone disorders
characterised by an excess of bone resorption.
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